STOCK TITAN
  1. Home
  2. News
  3. HCWB

HCW Biologics Inc - HCWB STOCK NEWS

Welcome to our dedicated news page for HCW Biologics (Ticker: HCWB), a resource for investors and traders seeking the latest updates and insights on HCW Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HCW Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HCW Biologics's position in the market.

News
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
Rhea-AI Summary
HCW Biologics Inc. reported financial results for Q4 and FY 2023, highlighting completion of key clinical studies on HCW9218 in cancer treatments. The company plans to initiate Phase 2 trials and expand into age-related disease studies. Despite positive clinical data, financial results show declining revenues due to licensee issues and increased R&D and G&A expenses. The company faced a net loss of $25.0 million in FY 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
earnings
-
News
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
Rhea-AI Summary
HCW Biologics Inc. (HCWB) reported financial results and business highlights for Q3 2023, including human data readout from Phase 1 clinical trial for HCW9218, expecting to complete initial phase of cancer studies in late 2023 or early 2024. Financial results show a decrease in revenues and R&D expenses, an increase in G&A expenses, and a net loss. The company holds $11.2 million in cash and cash equivalents, believing it has adequate capital to fund operations until the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.73%
Tags
earnings
-
News
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Rhea-AI Summary
HCW Biologics Inc. (HCWB) announced positive results from a Phase 1 clinical trial of HCW9218 in patients with advanced solid tumors, with 66% of ovarian cancer patients showing stable disease. The drug showed promise in activating immune cells and reducing TGF-β levels, supporting future Phase 2 studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
clinical trial
News
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
Rhea-AI Summary
HCW Biologics Inc. will present human data from an ongoing Phase 1 clinical trial of its lead product candidate, HCW9218, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The trial is evaluating HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors. The presentation will be made by Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology at the University of Minnesota. The poster will be available on the company's website after the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences clinical trial
-
News
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Rhea-AI Summary
HCW Biologics Inc. will provide an update on clinical development and intellectual property programs. Phase 1 clinical trial for HCW9218 in solid tumors is progressing well with no dose-limiting toxicity observed. Another ongoing trial for advanced pancreatic cancer is expected to be completed in H1 2024. The Company has been awarded five patents in the past year, protecting its lead product candidates and proprietary processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
News
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
earnings
News
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
none
-
News
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.93%
Tags
earnings
-
News
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
none
News
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
Stock HCWB logo
HCW Biologics Inc

Nasdaq:HCWB

HCWB Rankings

#4638 Ranked by Market Cap
#3781 Ranked by Stock Gains
N/A Ranked by Dividends

HCWB Stock Data

63.54M
17.84M
51.93%
2.82%
0.04%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Miramar

About HCWB

by leveraging our immunology expertise, hcw is developing proprietary immunotherapy candidates to address chronic inflammation through inflammasome modulation and senescent cell clearance.